創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 技術番号 技術名 技術概要
20/03/06 TGEM047 Innovative transparent film-forming and bioadhesive delivery technology TGEM047 is a versatile topical bioadhesive film-forming vehicle (platform) with occlusive or semi occlusive characteristics and sustained release properties for an adequate vehiculization of lipophilic and hydrophilic components. It can also be used as a vehicle for the inclusion of other technologies (micro, liposome, nanoparticles etc). This technology has been successfully applied to different topical molecules demonstrating an improvement on the API's bioavailability profile as well as providing more adequate formulations for patient treatment adherence. 問合せ
20/03/06 TGEM046 Proliferation control of Mononegavirales using photoswitching system Mononegavirales are promising tools as oncolytic vectors and transgene delivery vectors for gene therapy and regenerative medicine. By using the specifically designed proteins, which reversibly heterodimerize upon blue light illumination, photocontrollable mononegaviruses (measles and rabies viruses) were generated. The proteins were inserted into the flexible domain of the viral polymerase, and the oncolytic virus showed strong replication and oncolytic activities only when the viral polymerases were activated by blue light illumination. Treatment of this oncolytic virus resulted in a substantial reduction in tumor growth and prolonged survival under the blue light. 問合せ
20/03/06 TGEM045 Superior gene expression using photoswitching system Fusion system of CRISPR-dCpf1 and novel photoswitching system.
An improved split dCpf1 activator, which has the potential to activate endogenous genes more efficiently than a previously established dCas9 activator. The split dCpf1 activator can efficiently activate target genes in mice and provides an efficient and sophisticated genome manipulation in the fields of basic research and biotechnological applications.
問合せ
20/03/06 TGEM044 ON/OFF control of mice genome recombination using photoswitching system Fusion system of Cre–loxP recombination system and novel photoswitching system.
Enables sharp induction (up to 320-fold) of DNA recombination and is efficiently activated even by low-intensity illumination (~0.04 W m-2) or short periods of pulsed illumination (~30s).
Allows for efficient DNA recombination in an internal organ of living mice through noninvasive external illumination using an LED light source.
問合せ
20/03/06 TGEM043 ON/OFF control of gene expression using photoswitching system Fusion system of CRISPR-dCas9 and novel photoswitching system.
Enables high blue-light-inducible activation of endogenous target genes in various human cell lines.
Induced neuronal differentiation in iPS cells by achieving the activation of target genes.
問合せ
20/03/06 TGEM042 ON/OFF control of gene editing using photoswitching system Fusion system of CRISPR-Cas9 and novel photoswitching system.
Induces targeted genome sequence modifications through both nonhomologous end joining and homology-directed repair pathways in response to blue light irradiation and can be switched off simply by extinguishing the light.
Determines time-specific and location-specific activation by the irradiation.
問合せ
20/03/06 TGEM041 Novel photoswitching system for optogenetic control of gene editing and expression This system consisting of two proteins can control the activity of cellular proteins by the optogenetic method.
These new proteins were engineered to enhance light-induced heterodimerization and show faster kinetics than any of the other conventional dimerization-based blue spectrum photoswitches.
This is a powerful tool that can optogenetically manipulate molecular processes in biological systems.
問合せ
20/02/18 TGEM040 Genome editing technology using oligonucleotides The genome editing technology uses oligonucleotides only and requires neither protein nor double-strand break. Editing is highly selective and there are no by-product, which enables editing as intended without off-target risks. Easy administration to living body. 問合せ
20/02/12 TGEM039 Multi Targeted Drug Delivery using Peptide Drug Conjugates (PDC's) A novel Smart, Multi-Armed linker which is patented. The linker can bind up to three payloads –chemotherapeutic agents for treatment or fluorescent for diagnostics. The linker releases the payloads only in the Tumor cells and only after release the drugs become active and the fluorescent changes colors or starts to shine. We proved that Conjugates with dual drug payloads (multi-loading) resulted in enhanced cytotoxic effect towards cancer cells and less drug resistance evolved in comparison with mono-loaded counterparts. The novel linker can be used for PDC's, Antibody DC's(ADC's) and Nano-particle DC's(NDC's). An innovative technology for PDC's - a unique technology to synthesize cyclic peptides which are stable, selective and non-immunogenic. We can identify Receptors which are overexpressed in certain forms of cancer and synthesize peptides which will bind to these receptors so that we can use them for Targeted Drug Delivery. 問合せ
20/01/16 TGEM038 A novel cell therapy platform to regenerate tubular organs
Proprietary and biocompatible scaffold (temporary cell delivery device) is combined with a patient’s own cells (haematopoietic stem and precursor cells) to create an esophageal implant that could potentially be used to treat pediatric esophageal atresia and other conditions that affect the esophagus. TGEM038 can also be extended to other tubular organs, including the bronchi and trachea.
問合せ